Role of Protein Biomarkers in the Detection of High-grade Disease in Cervical Cancer Screening Programs

Overview

Journal J Oncol

Specialty Oncology

Date 2012 Apr 7

PMID 22481919

Citations 19

Authors

Charlotte A Brown

Johnannes Bogers

Shaira Sahebali

Christophe E Depuydt

Frans De Prins

Douglas P Malinowski

Affiliations

Soon will be listed here.

Abstract

Since the Pap test was introduced in the 1940s, there has been an approximately 70% reduction in the incidence of squamous cell cervical cancers in many developed countries by the application of organized and opportunistic screening programs. The efficacy of the Pap test, however, is hampered by high interobserver variability and high false-negative and false-positive rates. The use of biomarkers has demonstrated the ability to overcome these issues, leading to improved positive predictive value of cervical screening results. In addition, the introduction of HPV primary screening programs will necessitate the use of a follow-up test with high specificity to triage the high number of HPV-positive tests. This paper will focus on protein biomarkers currently available for use in cervical cancer screening, which appear to improve the detection of women at greatest risk for developing cervical cancer, including Ki-67, p16(INK4a), BD ProEx C, and Cytoactiv HPV L1.

Citing Articles

Label-free and label-based electrochemical detection of disease biomarker proteins.

Hanifa Lestari T, Irkham I, Pratomo U, Gaffar S, Zakiyyah S, Rahmawati I ADMET DMPK. 2024; 12(3):463-486.

PMID: 39091905 PMC: 11289512. DOI: 10.5599/admet.2162.

Role of ProEx C immunocytochemistry in cervical high-grade squamous intraepithelial lesions detection.

Ungureanu C, Socolov D, Anton G, Morosan E, Trandafir L, Lozneanu L Rom J Morphol Embryol. 2022; 62(4):1029-1034.

PMID: 35673822 PMC: 9289693. DOI: 10.47162/RJME.62.4.15.

Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening.

Johnson L, Saidu R, Svanholm-Barrie C, Boa R, Moodley J, Tergas A Cancer Epidemiol Biomarkers Prev. 2022; 31(3):595-603.

PMID: 35027434 PMC: 8901524. DOI: 10.1158/1055-9965.EPI-21-0972.

Human Papillomaviruses-Associated Cancers: An Update of Current Knowledge.

Pesut E, dukic A, Lulic L, Skelin J, Simic I, Milutin Gasperov N Viruses. 2021; 13(11).

PMID: 34835040 PMC: 8623401. DOI: 10.3390/v13112234.

Expression analysis of p16 and TOP2A protein biomarkers in cervical cancer lesions and their correlation with clinico-histopathological characteristics in a referral hospital, Tanzania.

Zuberi Z, Mremi A, Chilongola J, Semango G, Sauli E PLoS One. 2021; 16(10):e0259096.

PMID: 34705880 PMC: 8550370. DOI: 10.1371/journal.pone.0259096.

References

Dunton C, van Hoeven K, Kovatich A, Oliver R, Scacheri R, Cater J . Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia. Gynecol Oncol. 1997; 64(3):451-5. DOI: 10.1006/gyno.1996.4602. View

Bulkmans N, Berkhof J, Rozendaal L, van Kemenade F, Boeke A, Bulk S . Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370(9601):1764-72. DOI: 10.1016/S0140-6736(07)61450-0. View

Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M . Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer. 2006; 111(1):58-66. DOI: 10.1002/cncr.22420. View

Stoler M, Schiffman M . Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285(11):1500-5. DOI: 10.1001/jama.285.11.1500. View

Nieh S, Chen S, Chu T, Lai H, Fu E . Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol. 2003; 91(1):201-8. DOI: 10.1016/s0090-8258(03)00479-7. View

Petry K, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C . Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol. 2011; 121(3):505-9. DOI: 10.1016/j.ygyno.2011.02.033. View

Mayrand M, Duarte-Franco E, Rodrigues I, Walter S, Hanley J, Ferenczy A . Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357(16):1579-88. DOI: 10.1056/NEJMoa071430. View

Shi J, Liu H, Wilkerson M, Huang Y, Meschter S, Dupree W . Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol. 2007; 38(9):1335-44. DOI: 10.1016/j.humpath.2007.01.025. View

Guo M, Baruch A, Silva E, Jan Y, Lin E, Sneige N . Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol. 2011; 135(2):212-20. DOI: 10.1309/AJCP1LLX8QMDXHHO. View

10.

Cuzick J, Clavel C, Petry K, Meijer C, Hoyer H, Ratnam S . Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119(5):1095-101. DOI: 10.1002/ijc.21955. View

11.

Endl E, Gerdes J . The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000; 257(2):231-7. DOI: 10.1006/excr.2000.4888. View

12.

Serrano M, Hannon G, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366(6456):704-7. DOI: 10.1038/366704a0. View

13.

Halloush R, Akpolat I, Zhai Q, Schwartz M, Mody D . Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer. 2008; 114(6):474-80. DOI: 10.1002/cncr.23951. View

14.

Conesa-Zamora P, Domenech-Peris A, Ortiz-Reina S, Orantes-Casado F, Acosta-Ortega J, Garcia-Solano J . Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol. 2008; 62(2):159-62. DOI: 10.1136/jcp.2008.061408. View

15.

Hook S, Lin J, Dutta A . Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol. 2007; 19(6):663-71. PMC: 2174913. DOI: 10.1016/j.ceb.2007.10.007. View

16.

Ozaki S, Zen Y, Inoue M . Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol. 2011; 42(7):1007-12. DOI: 10.1016/j.humpath.2010.10.021. View

17.

Hilfrich R, Hariri J . Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol. 2008; 30(2):78-82. View

18.

Qiao X, Bhuiya T, Spitzer M . Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis. J Low Genit Tract Dis. 2005; 9(2):100-7. DOI: 10.1097/00128360-200504000-00006. View

19.

Sankaranarayanan R, Nene B, Shastri S, Jayant K, Muwonge R, Budukh A . HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360(14):1385-94. DOI: 10.1056/NEJMoa0808516. View

20.

Kelly D, Kincaid E, Fansler Z, Rosenthal D, Clark D . Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer. 2006; 108(6):494-500. DOI: 10.1002/cncr.22288. View